Affinergy develops site-specific biological delivery systems using biofriendly binders that can selectively adhere to proteins, cells and other biomaterial surfaces. Affinergy's multifunctional delivery systems offer unprecedented opportunities to target therapeutic delivery, functionalize medical devices, and enable a variety of diagnostic and biosensor applications. Affinergy is a Duke University spin-out company being incubated by BD (Becton, Dickinson and Company) and is headquartered in Research Triangle Park, NC. IDEA Fund Partners was an investor in the company's Series A financing.

Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures, and markets integrated molecular diagnostic systems.

UIQI2 is designed to develop and utilize in-house processes and technical infrastructure for the conduct of imaging-based multi-center trials. The main objective is to develop infrastructure within the University of Iowa, which will support the pulmonary imaging portion of government and industry-based multi-center trials. The target audience is government and corporate sponsored multi-centered pre-clinical and clinical trials; specifically the Pharmaceutical and Device sectors of the medical industry as well as large NIH trials.

Integrated Nano-Technologies specializes in developing creative solutions for diagnostic sample processing, and provides field personnel with fast, accurate test results that can improve biological identification.

Focal develops, manufactures and commercializes synthetic, absorbable, liquid surgical sealants based on the company's polymer technology. The company's FocalSeal-L and FocalSeal-S surgical sealant products are currently being developed for use inside the body to seal leaks resulting from lung, neurological, cardiovascular and gastrointestinal surgery.

Sober Steering develops transdermal technologies as means for detecting driver intoxication.